Lophius Biosciences GmbH, a Regensburg, Germany-based biotech company focusing on the development and marketing of innovative tools and diagnostic systems for functional assessment of disease-reactive T cells, raised €2M in funding.
The round was led by VRD GmbH, with participation of S-Refit AG.
The company intends to use the funds to further advance the clinical studies of its flagship product T-Track® CMV for the various clinical indications and to enable the further development of the pipeline products T-Track® TB (Tuberculosis) as well as T-Track® MS (Multiple Sclerosis).
Led by newly named CEO Dr. Robert Phelps, (previously Director Business Operations) has been appointed as new Chief Executive Officer and Chairman of the Board Prof. Dr. Ralf Wagner (formerly CEO), who will work closely together to create the commercial organization, Lophius Biosciences focuses on the development and marketing of innovative T cell based diagnostic systems for diagnosis and immunomonitoring. Its flagship product is T-Track®CMV, a diagnostic system intended to determine the functionality of the cell-mediated immune response in cytomegalovirus (CMV) seropositive transplant patients who undergo an immunosuppressive therapy.
FinSMEs
13/05/2014